Ocular adverse drug reactions

Expert Opinion on Drug Safety

Volumn 2, Issue 4, 2003, Pages 411-420

  Fraunfelder, F W ^a  

^a Casey Eye Institute and the National Registry of Drug Induced Ocular Side Effects   (United States)

Author keywords

adverse drug reactions (ADRs); ocular side effects; ocular toxicology; pharmacovigilance

Indexed keywords

DRUG;

CHEMICALLY INDUCED DISORDER; EYE DISEASE; HUMAN; PRACTICE GUIDELINE; REVIEW;

EYE DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS; PRACTICE GUIDELINES;

EID: 0141818235     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.4.411     Document Type: Review

References (43)

1. BRICK DC: Medication errors result in costly claims for ophthalmologists. Surv. Ophthalmol. (1995) 40(3):232-236.
2. BETTMAN JW: Seven hundred medicolegal cases in ophthalmology. Ophthalmology (1990) 97(10):1379-1384. (Pubitemid 20353986)
3. BETTMAN JW: A retrospective look at twenty-two medicolegal claims. How they might have been avoided. Surv. Ophthalmol. (1983) 28(1):55-60. (Pubitemid 13040876)
4. BETTMAN JW: Medicolegal claims in intraocular lens implant cases. Am. J. Ophthalmol. (1981) 91(5):620-621. (Pubitemid 11126091)
5. EDWARDS R, BIRIELL C: Harmonisation in pharmacovigilance. Drug Saf. (1994) 10(2):93-102. (Pubitemid 24045719)
6. FRAUNFELDER FT, FRAUNFELDER FW: Drug-induced ocular side effects (5th edn). Butterworth-Heinemann, Woburn, MA (2001):824.
7. FRAUNFELDER FT, MEYER SM: Amiodarone keratopathy. Trans. Ophthalmol. Soc. NZ (1984) 36:33-34.
8. MANTYJARVI M, TUPPURAINEN K, IKAHEIMO K: Ocular side effects of amiodarone. Surv. Ophthalmol. (1998) 42:360-366. (Pubitemid 28092776)
9. ARNOLD AC: Ischemic optic neuropathies. Ophthalmol. Clin. North Am. (2001) 14(1):83-98. (Pubitemid 32381754)
10. HAYREH SS: Anterior ischemic optic neuropathy: trouble waiting to happen. Ophthalmology (2000) 107(3):407-410. (Pubitemid 30191354)
11. KNOX DL, KERRISON JB, GREEN WR: Histopathologic studies of ischemic optic neuropathy. Trans. Am. Ophthalmol. Soc. (2000) 98:203-220. Discussion 221-222.
12. LESSELL S: Nonarteritic anterior ischemic optic neuropathy: enigma variations. Arch. Ophthalmol. (1999) 117(3):386-388. (Pubitemid 29133736)
13. NEWMAN NJ, SCHERER R, LANGENBERG P et al.: The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am. J. Ophthalmol. (2002) 134(3):317-328.
14. FEINER LA, YOUNGE BR, KAZMIER FJ, STRICKER BH, FRAUNFELDER FT: Optic neuropathy and amiodarone therapy. Mayo Clin. Proc. (1987) 62(8):702-717. (Pubitemid 17118782)
15. MACALUSO DC, SHULTS WT, FRAUNFELDER FT: Features of amiodarone-induced optic neuropathy. Am. J. Ophthalmol. (1999) 127(5):610-612. (Pubitemid 29215779)
16. FRAUNFELDER FW, FRAUNFELDER FT: Oculogyric crisis in patients taking cetirizine. Arch. Ophthalmol. (2003). Submitted.
17. ONUAGULUCHI G: Crises in post-encephalitic parkinsonism. Brain (1961) 84:395.
18. MARMOR MF, CARR RE, EASTERBROOK M: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology (2002) 109:1377-1382.
19. EASTERBROOK M: Detection and prevention of maculopathy associated with antimalarial agents. Int. Ophthalmol. Clin. (1999) 39:49-57. (Pubitemid 29222656)
20. EASTERBROOK M: Is corneal deposition of antimalarial any indication of retinal toxicity? Can. J. Ophthalmol. (1990) 25:249-251. (Pubitemid 20289523)
21. DRUKER BJ, SAWYER CL, KANTARJIAN HM: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N. Engl. J. Med. (2001) 344:1038-1042. (Pubitemid 32267973)
22. DRUKER BJ, TALPAZ M, RESTA DJ: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037. (Pubitemid 32267972)
23. HEINRICH MC, GRIFFITH DJ, DRUKER BJ: Inhibition of c-kit receptor tyrosine kinase activity by STI571: targeting BCE-ABL as therapy for CML. Oncologist (2000) 96:925-932. (Pubitemid 30618049)
24. MAURO MJ, DRUKER BJ: STI571: targeting BCE-ABL as therapy for CML. Oncologist (2001) 6:233-238. (Pubitemid 32592214)
25. VAN OOSTEROM A, JUDSON I, VERWEJ J: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a Phase I study. Lancet (2001) 358:1421-1423. (Pubitemid 33055745)
26. DEMETRI G, VON MEHRAN M, BLANKE CD: Efficacy and safety of imitanib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347:472-480. (Pubitemid 34879334)
27. HASSELBALCH HC: STI571 (Gleevec), a new drug for the treatment of chronic myeloid leukemia. Ugeskr. Laeger (2002) 164:2914-2917. (Pubitemid 34778200)
28. ESMAELI B, PRIETO VG, BUTLER CE et al.: Severe periorbital edema secondary to STI571 (Gleevec). Cancer (2002) 95(4):881-887. (Pubitemid 34839681)
29. FRAUNFELDER FW et al.: Ocular side effects associated with imatinib mesylate (Gleevec). J. Ocul. Pharmacol. Ther. (2003). Submitted.
30. MATHERS WD, SHIELDS WJ, SACHDEV MS, PETROLL WM, JESTER JV: Meibomian gland morphology and tear osmolarity: changes with accutane therapy. Cornea (1991) 10:286-290.
31. FRAUNFELDER FW, FRAUNFELDER FT: Isotretinoin and intracranial hypertension. Ophthalmology (2003). Submitted.
32. FRAUNFELDER FT, LABRAICO JM, MEYER SM: Adverse ocular reactions possibly associated with isotretinoin. Am. J. Ophthalmol. (1985) 100(4):534-537. (Pubitemid 16206982)
33. MACAROL V, FRAUNFELDER FT: Pamidronate disodium and possible ocular adverse drug reactions. Am. J. Ophthalmol. (1994) 118(2):220-224. (Pubitemid 24242456)
34. FRAUNFELDER FW, FRAUNFELDER FT, JENSVOLD B: Scleritis and other ocular side effects associated with pamidronate disodium. Am. J. Ophthalmol. (2003) 135(2):219-222. (Pubitemid 36151800)
35. FRAUNFELDER FW, FRAUNFELDER FT: Bisphosphonates and ocular side effects. N. Engl. J. Med. (2003) 348(12):1187-1188.
36. FRAUNFELDER FT, MEYER SM: Systemic reactions to ophthalmic drug preparations. Med. Toxicol. Adverse Drug Exp. (1987) 2(4):287-293. (Pubitemid 17140569)
37. FRAUNFELDER FT, MEYER SM: Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. Am. J. Ophthalmol. (1985) 99(3):362-363.
38. FRAUNFELDER FW, RICH LF: Possible adverse effects of drugs used in refractive surgery. J. Cataract Refract. Surg. (2003) 29(1):170-175. (Pubitemid 36152297)
39. FRAUNFELDER FW, FRAUNFELDER FT, JENSVOLD B: Adverse systemic effects from pledgets of topical ocular phenylephrine 10%. Am. J. Ophthalmol. (2002) 134(4):624-625. (Pubitemid 35304666)
40. LATIES AM, FRAUNFELDER FT: Ocular safety of Viagra, (sildenafil citrate). Trans. Am. Ophthalmol. Soc. (1999) 97:115-125. Discussion 125-128.
41. SANKAR PS, PASQUALE LR, GROSSKREUTZ CL: Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch. Ophthalmol. (2001) 119(8):1210-1211. (Pubitemid 32730014)
42. THAMBI L, KAPCALA LP, CHAMBERS W et al.: Topiramate-associated secondary angle-closure glaucoma: a case series. Arch. Ophthalmol. (2002) 120(8):1108. (Pubitemid 34856090)
43. FRAUNFELDER FW, FRAUNFELDER FT: Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology (2003). Submitted.